A genetics-led approach defines the drug target landscape of 30 immune-related traits

Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide associat...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Fang, H, De Wolf, H, Knezevic, B, Burnham, K, Osgood, J, Sanniti, A, Lledó Lara, A, Kasela, S, De Cesco, S, Wegner, J, Handunnetthi, L, McCann, F, Chen, L, Sekine, T, Brennan, P, Marsden, B, Damerell, D, O’Callaghan, C, Bountra, C, Bowness, P, Sundström, Y, Milani, L, Berg, L, Göhlmann, H, Peeters, P, Fairfax, B, Sundström, M, Knight, J
Fformat: Journal article
Iaith:English
Cyhoeddwyd: Springer Nature 2019

Eitemau Tebyg